Fig. 2.

Kaplan–Meier analysis of patients treated with DC and gemcitabine and correlation of survival with pre-vaccination immune response. a Three out of twelve patients were long-term survivors with survival times of more than 2 years. The median survival of all vaccinated patients was 10.5 months. One-year survival of the 12 patients receiving DC vaccination was 42%. b The capacity of lysate-loaded versus -unloaded DC to induce proliferation of T cells was used as a marker for the presence of a pre-vaccination antitumor immune response and expressed as stimulatory index (SI). Higher SIs correlated significantly with prolonged survival (P = 0.0036)